Nucleome Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bioescalator Innovation Building Univers...Website
www.nucleome.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Nucleome Therapeutics
Nucleome is an immunology company focused on addressing the root causes of immune-mediated inflammatory diseases through innovative genetic insights. Utilizing advanced 3D genomics technology, they link disease-associated genetic variants to the genes they affect, creating a comprehensive data atlas of immune system dysregulation. Their state-of-the-art facilities in Oxford, UK, enable expert scientists to validate findings and develop therapeutics aimed at restoring health. Nucleome's pipeline is dedicated to identifying causal genes that drive inflammation, paving the way for a new era of targeted treatments.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nucleome Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nucleome Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Nucleome Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Nucleome Therapeutics is spiking on competitors!
Check if Nucleome Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nucleome Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Nucleome Therapeutics has new funding data
Nucleome Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Nucleome Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Nucleome Therapeutics
Find 3 more new buyers
Compare Similar Companies to Nucleome Therapeutics
Compare insights from companies similar to Nucleome Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nucleome Therapeutics
<$5M
11-50
Private
$42.4M
2019
N/A
Company Profile Activity
Activity Insights
Nucleome Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nucleome Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nucleome Therapeutics.
Nucleome Therapeutics financials insights
Gather financial insights about Nucleome Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$42.4M
Nucleome Therapeutics Tech Stack
A closer look at the technologies used by Nucleome Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Open Position
Nucleome Therapeutics News & Media
Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer
Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead...Nucleome Therapeutics nominates first preclinical development candidate
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome's non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need OXFORD,...Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics OXFORD, England, Nov. 6, 2025 /PRNewswire/ -- Nucleome...ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium
ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health will host the 3rd Annual Dark Genome Symposium on Nov. 21 - 22 in New York, NY.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nucleome Therapeutics
Sign Up For FreeTo access detailed company insights
Nucleome is an immunology company focused on addressing the root causes of immune-mediated inflammatory diseases through innovative genetic insights. Utilizing advanced 3D genomics technology, they link disease-associated genetic variants to the genes they affect, creating a comprehensive data atlas of immune system dysregulation. Their state-of-th... Read More
